TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04585763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)
Description: The Shockwave Medical M5+ Peripheral IVL System is indicated for lithotripsy-enhanced, low-pressure balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. This device is not intended for use in coronary, carotid, or cerebrovascular arteries.
Study: NCT05415579

Intervention type: OTHER
Intervention: Traditional Chinese medicine (TCM)
Description: TCM treatment includes Chinese herbal medicine, acupuncture, moxibustion, massage, taiji, and qigong.
Study: NCT06407856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: The control group embarked on a conventional therapy regimen designed for patients with spastic diplegic cerebral palsy. This group will do 10reps of ROM exercises, 3 times stretching 30sec hold with 10sec rest and 5reps of strengthening exercises, standing , weight on one leg and raising the other leg to the side or behind, putting heel in front of your toe i.e., tandem stance, standing up and sitting down from a chair without using hands, walking while alternating knee lifts with each step.This group will do conventional therapy for 30 minutes a day, 3 times a week for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: The control group embarked on a conventional therapy regimen designed for patients with spastic diplegic cerebral palsy. This group will do 10reps of ROM exercises, 3 times stretching 30sec hold with 10sec rest and 5reps of strengthening exercises, standing , weight on one leg and raising the other leg to the side or behind, putting heel in front of your toe i.e., tandem stance, standing up and sitting down from a chair without using hands, walking while alternating knee lifts with each step.This group will do conventional therapy for 30 minutes a day, 3 times a week for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual Task Training
Description: Warming up exercise Supine Trunk and lower extremity ROM exercise Main exercise Sitting Base of support: balance cushion, ball Program: perform cognition task while maintaining balance (writing, drawing, puzzle etc.) Bench sitting (half ring P.) Base of support: balance pad Program: perform fine motor activities while maintaining balance (blocks assembly, scissoring, origami etc.) Standing Base of support: balance pad, balance cushion Program: perform eating while maintaining balance (drinking water, eat a snack etc.) Cool down exercise Supine Low extremity stretching \& deep breathing
Study: NCT04665102

Intervention type: OTHER
Intervention: Image classification using deep learning algorithm
Description: Image classification using deep learning algorithm
Study: NCT06487377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IX001 TCR-T cells
Description: IX001 TCR-T cell injection will be administered intravenously after lymphodepletion.
Study: NCT06114043

Intervention type: OTHER
Group type: OTHER
Intervention: Conservative treatment with orthopedic aid/wide shoe for participants with mild to moderate hallux valgus
Description: 60 participants will receive conservative treatment with orthopedic aid/wide shoe. Participants will be followed for 2 years.

Intervention type: OTHER
Group type: OTHER
Intervention: Operation for mild to moderate hallux valgus
Description: 60 participants will receive the traditional operative treatment for the deformity. Participants will be followed for 2 years.
Study: NCT05125939

Intervention type: OTHER
Intervention: Comparison of ADR
Description: The investigators will compare ADRs using traditional screening-restricted definition and combined screening, surveillance, and diagnostic indication (i.e., overall-non-FIT indication). The impact of addition of FIT+ indication into the overall indication (i.e., overall-FIT indication) on ADR will also be evaluated.
Study: NCT05379608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic-hyperoxic training
Description: IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~Each patient will undergo a hypoxic test to assess the individual response to hypoxia. The minimum safe SpO2 value is 82%, and the maximum allowable heart rate increase during exercise is + 50% of the starting value. When these parameters are reached, an automatic switch to the supply of a hyperoxic gas mixture (35-40% oxygen) occurs till the SpO2 level is 100%. During each training session a hypoxic gas mixture is supplied to the patient in an intermittent mode, alternating with the supply of a hyperoxic gas mixture. On average, each workout includes 6 of the above cycles. The total time of inhalation of a hypoxic gas mixture during one procedure is 20-30 minutes.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intermittent hypoxic-hyperoxic training/control
Description: IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~A control group of 30 patients will undergo a simulated IHHT course (with the same exposure time and number of sessions as intervention group - 15 sessions, 40-minutes long each, 5 workouts per week for 3 weeks). Patients of this group will breathe normoxic gas mixture (ordinary humidified air is supplied through the mask) during the entire session.
Study: NCT04835753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock wave
Description: true radial ESWT.A rESW pneumatic device (SHOCK MED, Italy) was used to provide one session per week (for a total of 12-week)

Intervention type: OTHER
Group type: OTHER
Intervention: traditional physical therapy program
Description: lower limbs muscles stretch and strength in addition to balance and gait training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy program
Description: lower limbs muscles stretch and strength in addition to balance and gait training
Study: NCT05721027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400 mg PO every 8 hours as needed for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400 mg PO every 8 hours as needed for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Dexamethasone 16 mg PO during ED visit and next day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational Intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
Study: NCT04795323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TARA v3.1, only non-pharmacological self-management support
Description: Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TARA v3.2, both non-pharmacological and pharmacological self-management support
Description: Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
Study: NCT06439290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phonosurgery
Description: Gender-affirming voice surgery (such as glottoplasty, cricothyroid approximation, thyroplasty and chondrolaryngoplasty), in addition to gender-affirming voice training and hormone therapy, plays an important role in achieving a gender-congruent voice in transgender and gender diverse people. In addition, these interventions are sometimes performed on cisgender men or women who wish to change their voice. However, the impact of these interventions on broad voice characteristics needs to be further investigated.
Study: NCT01344200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: In Phase I twenty (20) children will receive either celecoxib 14 or 7 mg/kg 120-180 minutes prior to lumbar puncture (LP). In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: In Phase I twenty (20) children will receive either celecoxib 14 or 7 mg/kg 120-180 minutes prior to lumbar puncture (LP). In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: In Phase I twenty (20) children will receive either celecoxib 14 or 7 mg/kg 120-180 minutes prior to lumbar puncture (LP). In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: In Phase I twenty (20) children will receive either celecoxib 14 or 7 mg/kg 120-180 minutes prior to lumbar puncture (LP). In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
Study: NCT06033664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fresh Funds
Description: Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.
Study: NCT04924790

Intervention type: BEHAVIORAL
Intervention: COVID-19 Pandemic
Description: Comparison of the intervention preferences of patients diagnosed with obstructive urinary stones in the urology clinic and recommended for intervention during and before COVID-19

Intervention type: BEHAVIORAL
Intervention: COVID-19 Pandemic
Description: Comparison of the intervention preferences of patients diagnosed with obstructive urinary stones in the urology clinic and recommended for intervention during and before COVID-19
Study: NCT06003179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning chemo at different doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning chemo at different doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Conditioning chemo at different doses

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TLI
Description: radiation given with conditioning chemo

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TLI
Description: radiation given with conditioning chemo

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TLI
Description: radiation given with conditioning chemo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine given as part of standard treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine given as part of standard treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine given as part of standard treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine given as part of standard treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine given as part of standard treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine given as part of standard treatment
Study: NCT06367413

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive three servings of carbohydrate per day during the 4-day experimental period. In specific, they will be supplemented with 0.31 gr of maltodextrin per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of maltodextrin per kg of body weight in the pre-sleep serving (1.1 gr maltodextrin/kg BW/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NAC
Description: Participants will receive three servings of N-acetylcysteine per day during the 4-day experimental period. In specific, they will be supplemented with 13.33 mg of N-acetylcysteine per kg of body weight per serving (40 mg NAC/kg BW/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NAC + Whey Protein
Description: Participants will receive three servings of N-acetylcysteine + whey protein per day during the 4-day experimental period. In specific, they will be supplemented with 0.31 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the pre-sleep serving (1.1 gr Whey protein + 40 mg NAC /kg BW/day).
Study: NCT05704985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DK210 (EGFR)
Description: Solution for SC administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DK210 (EGFR)
Description: Solution for SC administration
Study: NCT05194059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based physical activity
Description: Participants will follow a personalized activity pacing program
Study: NCT06481475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YY003
Description: Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YY003
Description: Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.
Study: NCT06560775

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard Treatment for SLE
Description: Standard Treatment for SLE

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Standard Treatment for SLE
Description: Standard Treatment for SLE
Study: NCT06545890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: continous infusion during surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: continous infusion during surgery
Study: NCT05704985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DK210 (EGFR)
Description: Solution for SC administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DK210 (EGFR)
Description: Solution for SC administration

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Short regimen radiation therapy (10 fractions or less)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune checkpoint blockers
Description: IV administration of approved PD1 blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Single agent or combination of not more than two
Study: NCT05305417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Regenerative Endodontic Treatment
Description: The intervention consist in achieve an access to the teeth root canal system, do a chemico-mechanical preparation each root canal for to be obturated with an autologous biological scaffold and bioactive biomaterials to maintain teeth free of signs/symptoms caused by pulp necroses and periapical lesions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Root Canal Treatment
Description: The intervention consist in achieve an access to the teeth root canal system, do a chemico-mechanical preparation each root canal for to be obturated with an inert biomaterial to maintain teeth free of signs/symptoms caused by pulp necroses and periapical lesions
Study: NCT05468489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab + chemotherapy (carboplatin-etoposide)
Description: Drug: Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~Drug: carboplatin and etoposide chemotherapeutics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab + chemotherapy (carboplatin-etoposide)
Description: Drug: Atezolizumab is a monoclonal antibody targeting PD-L1，developed by Roche Pharma AG.~Drug: carboplatin and etoposide chemotherapeutics
Study: NCT05520710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation
Description: A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Educational materials, designed to help people with traumatic brain injury manage their everyday cognitive challenges will be provided through Zoom video conferencing software.
Study: NCT05920902

Intervention type: OTHER
Intervention: routine therapy of acute ischemia stroke
Description: Routine therapy of acute ischemia stroke based on the guidelines, which generally includes two parts: evaluation and medicine treatment. Evaluation includes peripheral blood test, radiologic examination, electrophysiological examination, ultrasonic examination. Medicine treatment includes drug therapy and rehabilitation.
Study: NCT05361902

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive radiotherapy according to UPRATE protocol
Description: According to previously reported STAMPEDE trial (Parker et al.), patients will be treated with 6 weekly fractions of 6 Gy. According to local protocol the target will consist of prostate and entire seminal vesicles. Additional CT-scans will be made prior to and directly following each fraction. For more details, see study description
Study: NCT06206343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS application, Tele-rehabilitation treatment program
Description: Exercise training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS application, Tele-rehabilitation treatment program
Description: Exercise training
Study: NCT05334810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c
Description: DP303c injection, 3.0 mg/kg, every 3 weeks.
Study: NCT04028674

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Laryngeal Pacing Device
Description: Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Pacing Device
Description: Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
Study: NCT04930094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Description: Secukinumab 300 mg
Study: NCT05615974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM101
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM101
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM101
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously
Study: NCT05598047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive Functioning Training
Description: Those in the Executive Functioning Training Group will engage in exercises requiring one to set shift; that is, to maintain at least two sets of rules and decide which is appropriate to determine the response. In using these training exercises in the TOPS study, the effects size was quite large (d=-0.89). Dosage of 20 hours of training is considered an upper range on how much training is needed to produce an optimal therapeutic effect.